Misplaced Pages

GBR-12935

Identifiers
IUPAC name 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine
CAS Number	76778-22-8
PubChem CID	3456
IUPHAR/BPS	4639
ChemSpider	3338
UNII	9J9974WIBA
ChEBI	CHEBI:64093
ChEMBL	ChEMBL26320
CompTox Dashboard (EPA)	DTXSID2043743
Chemical and physical data
Formula	C28H34N2O
Molar mass	414.593 g·mol
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4
InChI InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2 Key:RAQPOZGWANIDQT-UHFFFAOYSA-N
(what is this?)  (verify)

GBR-12935 is a piperazine derivative which is a potent and selective dopamine reuptake inhibitor. It was originally developed in its H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain.

See also

• Vanoxerine
• GBR-12783
• GBR-13069
• GBR-13098
• DBL-583

References

1. Berger P, Janowsky A, Vocci F, Skolnick P, Schweri MM, Paul SM (January 1985). "GBR-12935: a specific high affinity ligand for labeling the dopamine transport complex". European Journal of Pharmacology. 107 (2): 289–90. doi:10.1016/0014-2999(85)90075-5. PMID 3979428.
2. Janowsky A, Vocci F, Berger P, Angel I, Zelnik N, Kleinman JE, et al. (August 1987). "GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease". Journal of Neurochemistry. 49 (2): 617–21. doi:10.1111/j.1471-4159.1987.tb02908.x. PMID 3598589. S2CID 25654981.
3. Zhu J, Green T, Bardo MT, Dwoskin LP (January 2004). "Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex". Behavioural Brain Research. 148 (1–2): 107–17. doi:10.1016/s0166-4328(03)00190-6. PMID 14684252. S2CID 20382190.
4. Swant J, Wagner JJ (2006). "Dopamine transporter blockade increases LTP in the CA1 region of the rat hippocampus via activation of the D3 dopamine receptor". Learning & Memory. 13 (2): 161–7. doi:10.1101/lm.63806. PMC 1409827. PMID 16585791.
5. Hsin LW, Chang LT, Rothman RB, Dersch CM, Jacobson AE, Rice KC (May 2008). "Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters". Journal of Medicinal Chemistry. 51 (9): 2795–806. doi:10.1021/jm701270n. PMC 5548119. PMID 18393401.

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Dopamine reuptake inhibitors
• 1-(2-(Diphenylmethoxy)ethyl)piperazines
• VMAT inhibitors
• Nervous system drug stubs